Introduction Biolexis Therapeutics is a biotech company founded by two veterans of both small molecule drug development and life science startups. Cancer biologist Dr. David Bearss is an expert in small-molecule drug development and the use of genetic model systems in drug discovery while Dr. Hariprasad Vankayalapati, a medicinal chemist, brings extensive knowledge and experience in identifying and developing lead candidates for drug discovery.
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Chemical drugs | 5 |
Immune cell therapy | 2 |
Biological products | 1 |
Degradable Molecular Glue | 1 |
Target |
Mechanism GLP-1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TGM2 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EIF2AK4 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MLX-7006 ( GLP-1R ) | Obesity More | IND Application |
SLX 3030 ( CDK9 ) | Castration-Resistant Prostatic Cancer More | Preclinical |
SLX 9000 ( TGM2 ) | Immune System Diseases More | Preclinical |
MLX4000 ( TNIK ) | Diabetes Mellitus, Type 2 More | Preclinical |
MLX 0800 ( AMPK ) | Obesity More | Preclinical |